Free tool
FAERS Monitor: Jesduvroq
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216951 or its brand name (Jesduvroq, Daprodustat). Reports on generic versions are filed under their own applications.
Reports
1,993
Serious
1,889
95% of reports
Hospitalization
1,051
Death reported
439
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hospitalisation299
- off label use166
- product use issue160
- death118
- haemoglobin decreased102
- renal impairment97
- cardiac failure94
- haemoglobin increased85
- dysphagia83
- nephrogenic anaemia73
- marasmus64
- cerebral infarction59
- fall57
- pneumonia51
- condition aggravated42
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2017 | 2 |
| 2018 | 23 |
| 2019 | 20 |
| 2020 | 12 |
| 2021 | 53 |
| 2022 | 47 |
| 2023 | 550 |
| 2024 | 487 |
| 2025 | 489 |
| 2026 | 310 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,166 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| marasmusSignal | 64 | 464.0 | 362.6 | 27,884 |
| haemoglobin increasedSignal | 85 | 200.4 | 162.4 | 16,356 |
| nephrogenic anaemiaSignal | 73 | 169.0 | 134.6 | 11,834 |
| cerebral infarctionSignal | 59 | 25.5 | 19.9 | 1,365 |
| hospitalisationSignal | 299 | 20.6 | 18.5 | 5,579 |
| cardiac failureSignal | 94 | 12.4 | 10.2 | 974 |
| renal impairmentSignal | 97 | 12.2 | 10.0 | 989 |
| haemoglobin decreasedSignal | 102 | 10.5 | 8.7 | 870 |
| dysphagiaSignal | 83 | 9.2 | 7.5 | 603 |
| product use issueSignal | 160 | 9.0 | 7.7 | 1,138 |
| off label useSignal | 166 | 2.0 | 1.7 | 86 |
| fall | 57 | 1.8 | 1.4 | 20 |
| pneumonia | 51 | 1.7 | 1.3 | 13 |
| condition aggravated | 42 | 1.5 | 1.1 | 6 |
| death | 118 | 1.4 | 1.2 | 16 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.